Navigation Links
Jules Musing to Lead Business Development Effort
Date:12/7/2011

NEWARK, Del., Dec. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that Jules A. Musing, an iBio Director, will assume a role as a Managing Director of the Company for at least the next six months in order to accelerate the Company's business development activity.  Mr. Musing, formerly a Senior Executive at Johnson & Johnson, joined iBio's Board of Directors in June of 2011.  In the course of his career in the Pharmaceutical and Biotechnology Industry, Mr. Musing has been President and Managing Director for Johnson & Johnson, Janssen Pharmaceutica, and Ares Serono companies.  At Johnson & Johnson, Mr. Musing was also responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances.  His activities included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.

In his role as an iBio Managing Director, Mr. Musing will focus on the Company's business development and licensing activities, including direct dealings with third parties and development of human and material resources to enlarge the Company's business development capacity.

"Jules will help us expand our business development capability rapidly to deal with the product candidates already developed on our platform and those we expect in the next few months," said Robert B. Kay, iBio's Chairman and CEO.  "We expect Jules' experience as a deal maker and his access to senior management in potential users of our technologies to lead to important business opportunities for us in a variety of U.S. and international markets. We are most fortunate to have his participation during this stage of our growth."

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative of most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

 Contacts: 

  

 

 Corporate:

Investor:

  

 

 Robert Erwin, President

Douglas Beck, CFO

 iBio, Inc.

iBio, Inc.

 302-355-2335

302-355-0923

 rerwin@ibioinc.com

ir@ibioinc.com

  


'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kronos Announces First Quarter Business Update and Financial Results
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. ImaRx Therapeutics Transitions Business Strategy
4. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
5. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
6. Small Business Innovation Research Program Awards Grant to Biomoda
7. American Dairy Provides Business Update
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Pharmos Issues Business Update on Dextofisopam Trial and Financing
10. One Call Now Offers Notification Service at NO CHARGE for Governments, Schools, Businesses, Religious Organizations and Others in Response to Swine Flu Outbreak
11. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SEOUL, South Korea , Feb. ... Macrogen, Inc. today announced they will form a ... for precision medicine in cancer. The goal of ... digital-sorting technology with Macrogen,s high-throughput Next Generation Sequencing ... the Clinical Laboratory Improvement Amendments (CLIA) of 1988 ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Yisrayl Hawkins, ... revealing article this week that uncovers what he says are the real facts surrounding ... of the Bible from parents and Sunday school teachers, and Yisrayl says there is ...
(Date:2/12/2016)... ... 12, 2016 , ... Planet Future is a Final Cut Pro ... great for showcasing pictures, videos as well as text in an exciting cartoon environment. ... transitions and a beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert ...
(Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the new ... under Dignity Health Arizona General Hospital , which opened last year in the ... new freestanding emergency room delivers the highest quality care to Mesa and the surrounding ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : Five Steps ... Mind” (published by Balboa Press) teaches readers how to become their own therapist. Providing ... author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s inner ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... use the action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its ... the Atlanta-area healthcare system. Details of the contract were not disclosed. , As ...
Breaking Medicine News(10 mins):